Expression and CpG island methylation pattern of MMP-2 and MMP-9 genes in patients with congenital factor XIII deficiency and intracranial hemorrhage

References

• Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev. 2016;30(6):461–475. doi: 10.1016/j.blre.2016.06.002
   PubMed Web of Science ®Google Scholar
• Alavi SER, Jalalvand M, Assadollahi V, et al. Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders – prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency. Semin Thromb Hemost. 2018;44(3):267–275. doi: 10.1055/s-0037-1604109
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Tabibian S, Shams M, et al. A unique factor XIII Mutation in Southeastern Iran with an unexpectedly high prevalence: Khash factor XIII. Semin Thromb Hemost. 2019 Jan 10. doi:10.1055/s-0038-1676580.
   Web of Science ®Google Scholar
• Dorgalaleh A, Alavi SE, Tabibian S, et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology. 2017;22(4):224–230. doi: 10.1080/10245332.2016.1263007
   PubMed Web of Science ®Google Scholar
• Gheidishahran M, Dorgalaleh A, Tabibian S, et al. Molecular diagnosis of factor XIII deficiency, data from comprehensive coagulation laboratory in Iran. Blood Coagul Fibrinolysis. 2018;29(1):87–91. doi: 10.1097/MBC.0000000000000679
   PubMed Web of Science ®Google Scholar
• Naderi M, Ahmadinejad M, Hosseini MS, et al. Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation. Blood Coagul Fibrinolysis. 2017;28(4):276–278. doi: 10.1097/MBC.0000000000000578
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Tabibian S, Sadat Hosseini M, et al. Diagnosis of factor xiii deficiency. Hematology. 2016;21(7):430–439. doi: 10.1080/10245332.2015.1101975
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol. 2016;95(3):451–455. doi: 10.1007/s00277-015-2568-8
   PubMed Web of Science ®Google Scholar
• Tokito A, Jougasaki M. Matrix metalloproteinases in non-neoplastic disorders. Int J Mol Sci. 2016;17(7):1178. doi: 10.3390/ijms17071178
   PubMed Web of Science ®Google Scholar
• Araki Y, Mimura T. Matrix metalloproteinase gene activation resulting from disordred epigenetic mechanisms in rheumatoid arthritis. Int J Mol Sci. 2017;18(5):905. doi: 10.3390/ijms18050905
   PubMed Web of Science ®Google Scholar
• Rosenberg GA. Metalloproteinases and neurodegenerative diseases: pathophysiological and therapeutic perspectives. Metalloproteinases Med. 2015;2:39–50. doi: 10.2147/MNM.S68849
   Google Scholar
• Wang J, Tsirka SE. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain. 2005;128:1622–1633. doi: 10.1093/brain/awh489
   PubMed Web of Science ®Google Scholar
• Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Stroke. 1998;29:1020–1030. doi: 10.1161/01.STR.29.5.1020
   PubMed Web of Science ®Google Scholar
• Hernandez-Guillamon M, Martinez-Saez E, Delgado P, et al. MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. Brain Pathol. 2012;22(2):133–141. doi: 10.1111/j.1750-3639.2011.00512.x
   PubMed Web of Science ®Google Scholar
• Naderi M, Younesi MR, Dorgalaleh A, et al. Association between expression of MMP-2 and MMP-9 genes and pathogenesis of intracranial hemorrhage in severe coagulation factor XIII deficiency. Hematology. 2015;20(8):487–492. doi: 10.1179/1607845414Y.0000000226
   PubMed Web of Science ®Google Scholar
• Keep RF, Zhou N, Xiang J, et al. Vascular disruption and blood–brain barrier dysfunction in intracerebral hemorrhage. Fluids Barriers CNS. 2014;11:18. doi: 10.1186/2045-8118-11-18
   PubMedGoogle Scholar
• Chicoine E, Esteve PO, Robledo O, et al. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Comun. 2002;297:765–772. doi: 10.1016/S0006-291X(02)02283-0
   PubMed Web of Science ®Google Scholar
• Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211:19–26. doi: 10.1002/jcp.20948
   PubMed Web of Science ®Google Scholar
• Farias LC, Gomes CC, Rodrigues MC, et al. Epigenetic regulation of matrix metalloproteinase expression in ameloblastoma. BMC Clin Pathol. 2012;12:11. doi: 10.1186/1472-6890-12-11
   PubMedGoogle Scholar
• Singh K, Agrawal NK, Gupta SK, et al. Differential expression of matrix metalloproteinase-9 gene in wounds of type 2 diabetes mellitus cases with susceptible – 1562 C > T genotypes and wound severity. Int J Low Extrem Wounds. 2014;13(2):94–102. doi: 10.1177/1534734614534980
   PubMed Web of Science ®Google Scholar
• Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol. 2003;53:731–742. doi: 10.1002/ana.10553
   PubMed Web of Science ®Google Scholar
• Abilleira S, Montaner J, Molina CA, et al. Matrix metalloproteinase – 9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg. 2003;99(1):65–70. doi: 10.3171/jns.2003.99.1.0065
   PubMed Web of Science ®Google Scholar
• Montaner J, Alvarez-Sabin J, Molina C, et al. Matrix met-alloproteinase expression is related tohemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32:2762–2767. doi: 10.1161/hs1201.99512
   PubMed Web of Science ®Google Scholar
• Castellanos M, Sobrino T, Mil-lian M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke. Stroke. 2007;38:1855–1859. doi: 10.1161/STROKEAHA.106.481556
   PubMed Web of Science ®Google Scholar
• Roach HI, Yamada N, Cheung KS, et al. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum. 2005;52:3110–3124. doi: 10.1002/art.21300
   PubMed Web of Science ®Google Scholar
• Alvarez-Sabín J, Delgado P, Abilleira S, et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage. Stroke. 2004;35(6):1316–1322. doi: 10.1161/01.STR.0000126827.69286.90
   PubMed Web of Science ®Google Scholar
• Silva Y, Leira R, Tejada J, et al. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke. 2005;36:86–91. doi: 10.1161/01.STR.0000149615.51204.0b
   PubMed Web of Science ®Google Scholar
• Castellazzi M, Tamborino C, De Santis G, et al. Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage. Acta Neurochir Suppl. 2010;106:137–140. doi: 10.1007/978-3-211-98811-4_24
   PubMedGoogle Scholar
• Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008;7(3):243–253. doi: 10.2174/187152708784936608
   PubMed Web of Science ®Google Scholar